A venture capital-backed Chinese biotech company recently occupied a new 4,500 square foot lab in Woburn as it ramps up hiring for its cancer research efforts.

The clinical-stage firm, Adlai Nortye, collaborates with Novartis and other drug makers on oncology programs. It joins Medtronic, MitraBiotech and Peritia Inc. among the biotech tenants at the 180,000-square-foot property owned by Woburn-based Cummings Properties.

Adlai Nortye in July announced it raised $53 million in series B financing from YuanMing Capital, Matrix Partners China, DT Capital Partners and Yahui Precision Medicine Fund.

Adlai Nortye, which also has a U.S. office in New Jersey, plans to have 10 employees working at the Woburn location by the end of the year.

“Woburn was my very first choice to build our lab,” said Zhihong Chen, the company’s vice president of cancer biology and pharmacology, in a statement. “We wanted to avoid the traffic and expensive overhead costs of Cambridge even though many biopharma companies choose to concentrate in that academically rich area.”

Cummings’ in-house design and construction teams provided the lab buildout for the fourth-floor corner location.